We are live on ! Find out more
STRO icon

Sutro Biopharma

134 hedge funds and large institutions have $819M invested in Sutro Biopharma in 2020 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 45 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

369% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 13

200% more funds holding in top 10

Funds holding in top 10: 26 (+4)

169% more capital invested

Capital invested by funds: $304M → $819M (+$515M)

150% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 18

96% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $763K

56% more funds holding

Funds holding: 86134 (+48)

0.14% more ownership

Funds ownership: 8.51%8.66% (+0.14%)

Holders
134
Holders Change
+48
Holders Change %
+55.81%
% of All Funds
2.37%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.11%
New
61
Increased
45
Reduced
18
Closed
13
Calls
$1.5M
Puts
$763K
Net Calls
+$732K
Net Calls Change
+$732K
Name Holding Trade Value Shares
Change
Change in
Stake
RWM
101
Ritholtz Wealth Management
New York
$260K +$199K +1,200 New
VOYA Investment Management
102
VOYA Investment Management
Georgia
$255K +$195K +1,176 New
Connor, Clark & Lunn Investment Management (CC&L)
103
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$241K +$184K +1,112 New
DekaBank Deutsche Girozentrale
104
DekaBank Deutsche Girozentrale
Germany
$233K +$182K +1,100 New
MCM
105
Manchester Capital Management
Vermont
$229K +$175K +1,056 New
Voloridge Investment Management
106
Voloridge Investment Management
Florida
$219K +$167K +1,009 New
MLICM
107
Metropolitan Life Insurance Company (MetLife)
New York
$188K
APA
108
American Portfolios Advisors
New York
$161K -$17.9K -108 -13%
FQ
109
First Quadrant
California
$152K +$16.4K +99 +17%
FIA
110
FNY Investment Advisers
New York
$151K +$116K +700 New
Ohio Public Employees Retirement System (OPERS)
111
Ohio Public Employees Retirement System (OPERS)
Ohio
$139K
BNP Paribas Financial Markets
112
BNP Paribas Financial Markets
France
$133K -$828 -5 -0.8%
Bank of Montreal
113
Bank of Montreal
Ontario, Canada
$111K +$51.8K +313 +261%
AA
114
AlphaCentric Advisors
Puerto Rico
$87K +$66.2K +400 New
Bank of America
115
Bank of America
North Carolina
$86K -$479K -2,894 -88%
Legal & General Group
116
Legal & General Group
United Kingdom
$68K +$3.31K +20 +7%
FC
117
FORA Capital
Florida
$56K +$42.7K +258 New
AIP
118
Ameritas Investment Partners
Nebraska
$48K
TRCT
119
Tower Research Capital (TRC)
New York
$45K -$270K -1,633 -89%
CMBA
120
C.M. Bidwell & Associates
Hawaii
$37K +$28.5K +172 New
SB
121
Samsara BioCapital
California
$36.4K
FF
122
FourThought Financial
Florida
$23K +$18.2K +110 New
LC
123
Lindbrook Capital
California
$22K +$16.6K +100 New
PCM
124
Penserra Capital Management
California
$19K +$14.9K +90 New
DWA
125
Dorsey Wright & Associates
California
$17K +$12.9K +78 New

STRO Hedge Fund Activity: Q4 2020 in Review

134 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2020, worth a combined $819M — up 169% from $304M a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new STRO positions and 13 closed out — a net gain of 48 holders — while 45 added to existing stakes and 18 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $36.9M. The largest seller was EcoR1 Capital, cutting an estimated $50M.

  • 134 institutional investors held Sutro Biopharma (STRO) as of Q4 2020, up from 86 in Q3 2020.
  • Funds reported $819M of Sutro Biopharma stock for Q4 2020, up 169% quarter-over-quarter.
  • 61 funds opened new Sutro Biopharma positions in Q4 2020 and 13 closed out, a net change of +48 holders.
  • The largest Sutro Biopharma buyer in Q4 2020 was Franklin Resources, an estimated $36.9M added.
  • The largest Sutro Biopharma seller in Q4 2020 was EcoR1 Capital, an estimated $50M sold.

Based on aggregated 13F filings for Q4 2020.